Yahoo
NasdaqGS - Delayed Quote USD

Upstream Bio, Inc. (UPB)

6.01 -0.07 (-1.15%)
At close: September 4 at 4:00:00 PM EDT
6.01 0.00 (0.00%)
After hours: September 4 at 7:30:02 PM EDT
Trade UPB on Coinbase
Chart Range Bar
Loading chart for UPB
  • Previous Close 6.08
  • Open 6.00
  • Bid 4.38 x 200
  • Ask 7.70 x 200
  • Day's Range 5.97 - 6.23
  • 52 Week Range 5.77 - 33.68
  • Volume 540,422
  • Avg. Volume 615,758
  • Market Cap (intraday) 329.174M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -2.88
  • Earnings Date (est.) Nov 4, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 33.50

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.

upstreambio.com

75

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

UPB
77.86%
S&P 500 (^GSPC)
12.75%

1-Year Return

UPB
69.46%
S&P 500 (^GSPC)
18.71%

3-Year Return

UPB
72.05%
S&P 500 (^GSPC)
70.93%

5-Year Return

UPB
72.05%
S&P 500 (^GSPC)
70.18%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 773k
Earnings -39.7M
Profit Margin -5,136.09%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-40M
-30M
-20M
-10M
0
-6000.0%
-5500.0%
-5000.0%
-4500.0%
-4000.0%

Analyst Insights

View More

Analyst Price Targets

9.00
33.50 Average
6.01 Current
75.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 9/2/2026
Analyst HC Wainwright & Co.
Rating Action Reiterates
Rating Buy
Price Action Maintains
Price Target 36 -> 36

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (5yr expected)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -30.28%

  • Return on Equity (ttm)

    -46.05%

  • Revenue (ttm)

    3.16M

  • Net Income Avi to Common (ttm)

    -156.5M

  • Diluted EPS (ttm)

    -2.88

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    261.31M

  • Total Debt/Equity (mrq)

    0.35%

  • Levered Free Cash Flow (ttm)

    -86.62M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: